Transforming growth factor B (TGFB) plays a key role in maintaining tissue homeostasis by inducing cell cycle arrest, differentiation and apoptosis, and ensuring genomic integrity. Furthermore, TGFB orchestrates the response to tissue injury and mediates repair by inducing epithelial to mesenchymal transition and by stimulating cell motility and invasiveness. Although loss of the homeostatic activity of TGFB occurs early on in tumor development, many advanced cancers have coopted the tissue repair function to enhance their metastatic phenotype. How these two functions of TGFB become uncoupled during cancer development remains poorly understood. Here, we show that, in human keratinocytes, TGFB induces phosphorylation of Smad2 and Smad3 as well as Smad1 and Smad5 and that both pathways are dependent on the kinase activities of the type I and II TGFB receptors (TBR). Moreover, cancer-associated missense mutations of the TBRII gene (TGFBR2) are associated with at least two different phenotypes. One type of mutant (TGFBR2 E526Q ) is associated with loss of kinase activity and all signaling functions. In contrast, a second mutant (TGFBR2 R537P
Introduction
In normal epithelia, transforming growth factor h (TGFh) plays a key role in maintaining tissue homeostasis by inducing cell cycle arrest, differentiation, and apoptosis and ensuring genomic integrity. In this manner, TGFh functions as a tumor suppressor. In addition, TGFh orchestrates the response to tissue injury and mediates repair by inducing epithelial to mesenchymal transition (EMT) and by increasing cell motility and invasiveness in a timeand space-limited manner. Escape from the tumor-suppressive actions of TGFh seems to be an early and frequent event in carcinogenesis (1) . Although tumor cells are generally refractory to TGFh-mediated growth arrest, many retain other functions involved in tissue repair, such as EMT and migration (2) . In this case, the TGFh pathway acts in a pro-oncogenic manner to promote the invasive and metastatic tumor phenotype. Although this uncoupling of the two arms of the TGFh effector pathway frequently occurs in cancer, the underlying molecular mechanisms have remained elusive. Approximately 40 different cancer-associated missense mutations of the TGFh type II receptor (ThRII) gene (TGFBR2) have been reported, and the vast majority of these mutations are clustered within the receptor kinase domain (3, 4) . To determine whether some of these mutations are associated with an oncogenic gain of function, we undertook a detailed analysis of two human head and neck squamous cell carcinoma (HNSCC) lines, A253 and SqCC/Y1, which had been previously reported to carry missense mutations in subdomain XI of the receptor kinase (5) . A253 cells are homozygous for a TGFBR2 mutation that results in a substitution of arginine to proline at codon 537 (R537P), whereas SqCC/Y1 cells are homozygous for a TGFBR2 mutation that encodes a glutamate to glutamine change at position 526 (E526Q). SqCC/Y1 cells were completely unresponsive to TGFh. In contrast, although A253 cells were also refractory to TGFh-mediated growth arrest, they were constitutively in an EMT-like state and highly motile and invasive. Moreover, this phenotype could be directly ascribed to the constitutive activation of bone morphogenic protein (BMP)-Smads, Smad1 and Smad5, and could be reversed using a dual ThRI/II kinase inhibitor. Identification of such activated ThRII receptor mutations in tumors has direct implications for appropriately targeting these cancers with selective therapeutic molecules.
with 1% fetal bovine serum (FBS) as described by Pirisi et al. (6) . T47D human breast carcinoma cells were obtained from the American Type Culture Collection and maintained in RPMI 1640 (Invitrogen Corp.) supplemented with 10% (v/v) FBS and gentamicin (10 Ag/mL). WI-38 human lung fibroblasts were maintained in DMEM supplemented with 10% (v/v) FBS.
Detection of Smad proteins by Western blot. Western blot analyses were carried out as previously described (7) . Smad proteins were detected using mouse monoclonal anti-Smad2 (1:1,000; Cell Signaling), anti-Smad3 (1:500; Invitrogen/Zymed), and rabbit monoclonal anti-Smad1 (1:500) and anti-Smad5 (1:1,000; Epitomics) antibodies. Phosphorylated Smads were detected using rabbit monoclonal anti-pSmad2 (1:1,000), rabbit polyclonal anti-pSmad3 (1:1,000), and rabbit polyclonal anti-pSmad1/5 (1:1,000) antibodies (Cell Signaling). ThRII protein was detected using a rabbit polyclonal ThRII (1:200; Santa Cruz Biotechnology) antibody.
Smad dephosphorylation assays. Following treatment of cells with TGFh (100 pmol/L) for 1 h, the medium was replaced with fresh medium followed by treatment with SD-093 (1 Amol/L), NPC-30345 (10 Amol/L), SB-431542 (10 Amol/L), or LY2109761 (2 Amol/L) for various time points (0-5 h). Whole-cell extracts or nuclear and cytoplasmic fractions (Active Motif Nuclear Extraction kit, Active Motif North America) were subjected to Western blot analysis of Smad proteins as described above.
Gene silencing by small interfering RNA transfection. Transfections were performed in 24-well cluster dishes using cultures at 70% to 80% confluence. GAPDH-specific, control pooled-specific, and Smad-specific small interfering RNAs (siRNA) were obtained from Dharmacon, Inc. Transfection conditions were optimized using GAPDH siRNA according to the manufacturer's protocol. Optimal gene silencing was achieved when transfections were performed using the DF1 reagent (1.5 AL/well) under sterile RNase-free conditions. Twenty-four hours following transfection, cells were lysed and protein extracts were subjected to Western blot analysis as described above. For TGFh-induced Smad phosphorylation analysis, TGFh (100 pmol/L) was added 24 h following transfection, and the experiment was terminated 24 h later.
Detection of filamentous actin and E-cadherin. Cells were plated in chamber slides and allowed to adhere overnight. Following treatment with TGFh (100 pmol/L), SD-093 (1 Amol/L), or LY2109761 (2 Amol/L), TGFh plus inhibitor, or vehicle only for 72 h, filamentous actin (F-actin) was detected using Alexa Fluor 488 phalloidin (Molecular Probes) and E-cadherin was detected using anti-E-cadherin antibody (Transduction Laboratories) as previously described (8) .
Cell migration and invasion assays. Cell migration and invasion assays were performed in MCDB153 ++ culture medium supplemented with 1% (v/v) FBS as previously described (8) .
Cell proliferation assays. A total of 10 4 cells were plated in duplicate wells of 24-well plates and allowed to adhere overnight. Cells were then treated with dual ThR kinase inhibitor, LY2109761, at concentrations ranging from 0 to 2,000 nmol/L for 96 h. Cell numbers were determined using a Model 0039 Coulter Counter (Beckman Coulter).
Detection of Smad proteins in A253 xenografts in vivo. Exponentially growing A253 tumor cells (1 Â 10 6 ) were injected s.c. into the flank of viral antibody-free 5-to 6-wk-old athymic nude mice (Harlan Laboratory). Once tumors reached a size of f0.5 cm, mice were sacrificed and tumors were excised, fixed, and embedded into paraffin. For immunostaining, 5-Am sections were prepared and processed as previously described (9) . Phosphorylated Smads were detected using rabbit monoclonal anti-pSmad2 (1:200) and rabbit polyclonal anti-pSmad1/5 (1:200) antibodies (Cell Signaling).
RNA extraction and reverse transcription-PCR. RNA was extracted from HaCaT, A253, SqCC/Y1, and WI-38 cell lines using the Qiagen RNeasy RNA Extraction kit (Qiagen, Inc.). Reverse transcription-PCR (RT-PCR) for Alk-1, Alk-2, Alk-3, Alk-5, and Alk-6 was performed using 25 ng total RNA using the Qiagen OneStep RT-PCR kit. The following primers were used: Alk-1, 5 ¶-GGCTCCCCCAGGAAAGGCCTT ( forward) and 5 ¶-GGACTCTCC-CAGCTCGCTGTG (reverse); Alk-2, 5 ¶-GTAGATGGAGTGATGATTCTT ( forward) and 5 ¶-AGGGAAGGATTTTCCTTTAGT (reverse); Alk-3, 5 ¶-TTGGG-AGCCTATTTGTTCATC ( forward) and 5 ¶-TTGGGAGCCTATTTGTTCATC (reverse); Alk-5, 5 ¶-CACCTCTGTACAAAAGACAAT ( forward) and 5 ¶-GCAG-ATATAGACCATCAACAT (reverse); and Alk-6, 5 ¶-CGTCCAAAGGTCTTGC-GTTGT ( forward) and 5 ¶-AGCCCTGTGGTGTATAGGTCC (reverse).
Site-directed mutagenesis. A 4.63-kb EcoRI fragment containing the full-length cDNA sequence of the human TGFR2 gene was excised from pH2-3FF (obtained from H. Lodish, Whitehead Institute, Cambridge, MA) and subcloned into pcDNA3 at the EcoRI site. The 1.8-kb amino acid coding sequence of ThRII was then amplified by PCR using primers that contained a KpnI site at the 5 ¶ end and an EcoRI site at the 3 ¶ end. The PCR product was digested with KpnI and EcoRI and then ligated into pcDNA3 at the KpnI/EcoRI sites. The resulting construct (TBRII/pcDNA3) was then used to generate specific mutants using the QuikChange II XL Site-Directed Mutagenesis kit (Stratagene). Forward and reverse primers were designed to generate the individual mutants, E526Q and R537P. In addition, a HaeII site was introduced in the E526Q-specific primers, whereas a XhoI site was introduced into the R537P-specific primers to allow initial screening of mutant clones. Mutations in plasmid DNA were confirmed by restriction digestion and DNA sequencing at the Cancer Institute of New Jersey DNA Synthesis and Sequencing Shared Resource.
Reporter gene assays. Cloned TGFBR2 mutants and/or wild-type receptors were expressed in the TGFBR2-null T47D human breast carcinoma cells using transient transfection with Lipofectamine 2000 (Invitrogen) as previously described (5, 10) . The following TGFh-responsive reporter genes were used: p3TP-lux (gift from Dr. Michael Centrella, Yale University, New Haven, CT), SBE4-luc (obtained from Dr. Bert Vogelstein, Johns Hopkins University, Baltimore, MD), Col7A1-luc (obtained from Dr. Alain Mauviel, Institut National de la Sante et de la Recherche Medicale U697, Paris, France), and pDel-5-myc-luc (gift from Dr. Fang Liu, Rutgers University, Piscataway, NJ).
Results
We first examined the effects of TGFh superfamily members on Smad activation in human keratinocytes. HaCaT cells expressed a basal level of phosphorylated Smad2 and Smad3 even in the absence of exogenous TGFh (Fig. 1A, left) . As expected, TGFh treatment resulted in a robust activation of Smad2 and Smad3. In addition, and quite unexpectedly, TGFh treatment also induced phosphorylation of the classic BMP pathway Smads, Smad1 and Smad5 (Fig. 1A, left) . The identity of pSmad1 and pSmad5 was confirmed using a pSmad1/5-directed antibody that does not cross-react with pSmad3. Furthermore, treatment of cells with BMP2 induced phosphorylation of Smad1 and Smad5, coincident with those induced by TGFh treatment. Conversely, activin A only activated Smad2 and Smad3 but failed to induce pSmad1 and pSmad5. The kinase inhibitor SD-093 inhibits not only the ThRI (Alk-5) kinase but also the related activin type I receptor kinases Alk-4 and Alk-7. Pretreatment of cells with SD-093 inhibited both TGFh-and activin-induced phosphorylation of Smad2 and Smad3 (Fig. 1A, left) . Importantly, SD-093 treatment also inhibited TGFhmediated induction of pSmad1 and pSmad5, indicating that their phosphorylation was dependent on ThRI (Alk-5) activity. BMP2-induced Smad1 and Smad5 phosphorylation was not affected, consistent with the fact that SD-093 does not target BMP type I receptors (8) .
We previously described two human squamous carcinoma cell lines (SqCC/Y1 and A253) that are homozygous for missense TGFBR2 gene mutations (5) . Although endogenous autophosphorylated wild-type ThRII and transphosphorylated ThRI could be detected in HaCaT cells (5) , neither receptor species was phosphorylated in SqCC/Y1 TGFBR2 E526Q -mutant cells. On the other hand, in A253 TGFBR2
R537P
-mutant cells, the levels of both ThRII and ThRI phosphoproteins were significantly higher than in HaCaT cells independently of the presence of exogenous TGFh (5).
Thus, the TGFBR2 R537P mutation seems to constitutively activate the ThRII kinase.
To further characterize the two mutant receptors, we examined their effects on Smad activation. In SqCC/Y1 TGFBR2 E526Q -mutant cells, TGFh treatment failed to induce phosphorylation of any of the receptor-associated Smad (R-Smad) proteins (Fig. 1A, right) . In contrast, treatment with activin induced pSmad2 and pSmad3, which was inhibitable by SD-093. Similarly, treatment with BMP2 resulted in activation of pSmad1 and pSmad5, which was not affected by SD-093 treatment. Thus, in SqCC/Y1 cells, TGFh fails to activate any of the R-Smads, whereas activin and BMP2 retained the ability to induce phosphorylation of their respective target Smads.
As in SqCC/Y1 cells, treatment of A253 TGFBR2
-mutant cells with TGFh failed to induce phosphorylation of pSmad2 and pSmad3 (Fig. 1A, middle) . In contrast, A253 cells constitutively expressed high levels of pSmad1 and pSmad5 (Fig. 1A, middle) . BMP2 treatment resulted in further increasing the level of these same two phosphoproteins, which was not affected by SD-093 treatment. On the other hand, activin treatment resulted in a modest induction of pSmad2 and pSmad3, inhibitable by SD-093, but not of pSmad1 or pSmad5. Thus, neither the activin nor the BMP pathways seem to be affected by the presence of the TGFBR2 R537P mutant. To further substantiate that the bands detected by both the antipSmad3 and anti-pSmad1/5 antibodies in HaCaT and A253 cell and pSmad3 (pS3 ) as well as of pSmad1 (pS1 ) and pSmad5 (pS5), all of which were blocked by SD-093 pretreatment. A253 and SqCC/Y1 expressed no detectable pSmad2 or pSmad3 even in response to TGFh. Note that the pSmad3-directed antibody that was raised against the COOH-terminal phosphorylation site of Smad3 cross-reacts to some extent with the BMP-Smads Smad1 and Smad5. Thus, the upper band recognized by the pSmad3 antibody in HaCaT cells most likely represents pSmad1, whereas the lower band represents pSmad3 and/or pSmad5, which are so close in molecular size that they seem to comigrate. Whereas SqCC/Y1 cells expressed very little pSmad1 and pSmad5, A253 cells constitutively expressed high levels of pSmad1 and pSmad5 (detected by either anti-pSmad1/5 or anti-pSmad3). This BMP-Smad activation was unaffected by SD-093. Control experiments included treatment of HaCaT, A253, and SqCC/Y1 cells with activin A (50 ng/mL) for 1 h, which resulted in activation of Smad2 and Smad3. Pretreatment with SD-093 resulted in blocking this activation in each of the lines. Conversely, BMP2 (100 ng/mL) treatment for 1 h resulted in induction of BMP-Smads Smad1 and Smad5 in each of the cell lines, which was not blocked by SD-093 pretreatment. B, transient transfection of Smad-specific siRNA (siSmad) resulted in effectively reducing the level of total Smad protein in a dose-and time-dependent manner for up to 72 h (data not shown). Compared with untransfected cells, as little as 25 nmol/L siSmad was sufficient to knock down the Smad target, whereas 100 nmol/L of control scrambled siRNA had no effect. Furthermore, the effect of any of the siSmads was specific to the Smad target because the levels of closely related Smads were unaffected. In both HaCaT and A253 cells, transient transfection of siRNA specific to Smad1 or to Smad5 resulted in a significant reduction of total Smad1 and Smad5 protein levels, respectively, whereas control pool siRNA had no effect. In addition, cotransfection of siSmad1 (siS1 ) and siSmad5 (siS5 ) effectively silenced both Smads and resulted in loss of both phosphorylated Smad species. Most importantly, these results show that the activated pSmads in A253 represent pSmad1 and pSmad5 but not pSmad3.
extracts did, in fact, represent pSmad1 and pSmad5 and not pSmad3, we silenced endogenous Smad expression using specific siRNAs (Fig. 1B) . Silencing endogenous Smad1 and/or Smad5 expression using specific siRNAs abrogated the ability of TGFh to induce pSmad1 and pSmad5 in HaCaT cells and resulted in the loss of the constitutively phosphorylated BMP-Smads in A253 cells (Fig. 1B) . In contrast, silencing of Smad3 did not affect the ability of TGFh to induce phosphorylation of Smad1 and Smad5 in HaCaT cells nor did it affect the levels of phosphorylated Smad1 or Smad5 in A253 cells (data not shown). These results further substantiate that the constitutively expressed pSmads in A253 cells indeed represent pSmad1 and pSmad5 and not pSmad3.
Because SD-093 treatment did not affect the level of the constitutively active BMP-Smads in A253 cells, we investigated the possibility that the elevated levels of activated BMP-Smads might be due to a reduced rate of dephosphorylation ( Fig. 2A) . As expected, TGFh treatment induced a robust activation of Smad2, Smad3, Smad1, and Smad5 in HaCaT cells (time ''0, '' Fig. 2A ). On Figure 2 . Dephosphorylation of activated Smads. A, assays were performed as described in Materials and Methods. In HaCaT cells, inhibition of ThRI (Alk-5) kinase activity using the selective inhibitor SD-093 resulted in dephosphorylation of activated pSmad2 and pSmad3 with a t 1/2 of 45 min. In addition, TGFh-induced pSmad1 and pSmad5 were dephosphorylated in response to SD-093 treatment. SqCC/Y1 and A253 cells failed to express pSmad2 and pSmad3. Note that constitutive pSmad activation detected by anti-pSmad3 antibody in SqCC/Y1 cells is a result of longer exposure because these cells lacked pSmad1 and pSmad5. In contrast, treatment of A253 cells with SD-093 for up to 5 h failed to affect the constitutive level of pSmad1 and pSmad5. Total Smad proteins were detected using specific antibodies to Smad1, Smad5, Smad3, and Smad2, indicating that these proteins are expressed in each of the lines. B, results obtained using SD-093 were confirmed using other selective ThRI kinase inhibitors SB-431542 (10 Amol/L) and NPC-30345 (10 Amol/L). In HaCaT cells, TGFh-dependent activated Smad2, Smad3, Smad1, and Smad5 underwent rapid dephosphorylation on treatment with either inhibitor. On the other hand, in A253 cells, pSmad1 and pSmad5 levels were unaffected by either of the two inhibitors. C, following dephosphorylation assays performed using SD-093 as described above, extracts were separated into cytoplasmic and nuclear fractions using the Active Motif Nuclear Extraction kit. In HaCaT, TGFh-activated Smad2 and Smad3 as well as Smad1 and Smad5 were predominantly localized in the nucleus. Activated Smads underwent rapid dephosphorylation in response to SD-093 (1 Amol/L) treatment. In contrast, in A253 cells, nuclear pSmad1 and pSmad5 showed little to no dephosphorylation in response to SD-093. D, in HaCaT cells, TGFh-activated pSmad2 and pSmad3 as well as pSmad1 and pSmad5 were dephosphorylated by treatment with the dual ThRI/II inhibitor LY2109761 with a t 1/2 of 45 min. In A253 cells, pSmad1 and pSmad5 underwent dephosphorylation in response to LY2109761 treatment with kinetics similar to HaCaT cells.
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www.aacrjournals.org ThRI (Alk-5) blockade using SD-093, all activated R-Smads were rapidly dephosphorylated with a half-life (t 1/2 ) of f45 min, indicating that their phosphorylation state was also dependent on ThRI (Alk-5) kinase activity ( Fig. 2A) . In contrast, in A253 cells, the constitutively activated BMP-Smads (Smad1 and Smad5) were resistant to dephosphorylation in response to SD-093 treatment. Similar results were obtained using two other ThRI (Alk-5/4/7) kinase inhibitors from different chemical classes, SB-431542 and NPC-30345, indicating that resistance to dephosphorylation was not unique to this particular inhibitor ( Fig. 2B; refs. 8, 11, 12) . Thus, constitutive activation of pSmad1 and pSmad5 in A253 cells seems to have become independent of exogenous TGFh as well as (ThRI) Alk-5 kinase activity.
Following 1 h of TGFh treatment, HaCaT cell nuclei were strongly enriched for pSmad2 and pSmad3 as well as pSmad1 and pSmad5. These activated Smads underwent subsequent dephosphorylation in response to SD-093 treatment associated with a rapid reduction of total Smad2 and Smad3 levels in the nucleus, consistent with export of dephosphorylated Smads back into the cytoplasm (Fig. 2C) . Although little or no pSmad2 or pSmad3 was detected in the nuclei of A253 cells, the nuclear fraction was highly enriched for pSmad1 and pSmad5 (Fig. 2C ). In addition, SD-093 treatment had minimal effect on dephosphorylation of these activated BMP-Smads (Fig. 2C) . To determine whether the TGFBR2 R537P mutant might be responsible for the constitutive activation of BMP-Smads in A253 cells, we made use of LY2109761, a dual inhibitor that targets both the ThRII and ThRI kinases but does not affect BMP-induced cellular responses (13) . In HaCaT cells, treatment with LY2109761 caused rapid dephosphorylation of all TGFh-activated R-Smads (Fig. 2D) . In sharp contrast to the lack of effect of SD-093 on pSmad1 and pSmad5 levels in A253 cells ( Fig. 2A) , treatment with LY2109761 resulted in rapid dephosphorylation of these BMP-Smads (Fig. 2D) . Therefore, we tentatively concluded that the effects of LY2109761 on pSmad1 and pSmad5 levels were mediated by its inhibition of the ThRII receptor rather than ThRI (Alk-5), thereby resulting in dephosphorylation of pSmad1 and pSmad5.
TGFh-induced EMT, which is an important event during wound healing, can be retained in cancer progression (14) . F-actin stress fiber formation and loss or redistribution of E-cadherin are hallmarks of EMT (14) . As expected, treatment of HaCaT cells with TGFh resulted in actin stress fiber formation and a redistribution of E-cadherin from the cell membrane to the cytoplasmic compartment (Fig. 3A) . Furthermore, these TGFh-induced responses were dependent on ThRI (Alk-5) kinase activity, as the phenotype could be reversed by either SD-093 or LY2109761. In fact, treatment with either of these kinase inhibitors alone resulted in a more cohesive epithelioid morphology with a more pronounced submembranous localization of F-actin and cell surface expression of E-cadherin compared with vehicle (DMSO)-treated controls. In SqCC/Y1 cells, F-actin and E-cadherin were both present at the membrane and the cells had a fairly typical epithelioid morphology (Fig. 3A) . In addition, there was no demonstrable change in phenotype in response to either TGFh or kinase inhibitor treatment (Fig. 3A) . In contrast, in A253 cells, F-actin was diffusely expressed throughout the cytoplasm (Fig. 3A) and E-cadherin predominantly in a cytoplasmic and perinuclear pattern independently of exogenous TGFh (Fig. 3A) . More importantly, LY2109761 treatment resulted in redistribution of F-actin toward the cell periphery and of E-cadherin to the cell membrane, whereas SD-093 had no effect. Moreover, treatment of A253 cells with LY2109761 alone (in the absence of exogenous TGFh) induced a more cohesive epithelioid morphology with distinct cell boundaries. Thus, the TGFBR2 R537P mutant seems to endow A253 with an EMT-like state that is selectively reversible by the dual ThR kinase inhibitor and seems to be dependent on constitutive activation of pSmad1 and pSmad5.
As shown in Fig. 3B , TGFh treatment of HaCaT cells resulted in a 10-fold increase in the rate of cell migration, which could be inhibited by either SD-093 or LY2109761 (Fig. 3B) . In contrast, SqCC/Y1 cells displayed very little cell migration, which was not affected by TGFh nor by SD-093 or LY2109761 treatment (Fig. 3B) . In contrast, A253 cells displayed a very high basal rate of cell migration independently of exogenous TGFh (Fig. 3B) . Moreover, whereas SD-093 had no effect on migration of A253 cells, LY2109761 inhibited migration by f50% (P < 0.001). With respect to invasion into Matrigel matrix, SqCC/Y1 cells were completely noninvasive for periods up to 72 h (data not shown). In contrast, A253 cells were highly invasive (Fig. 3C) . Moreover, A253 invasiveness was reduced by f50% by LY2109761 treatment but not by SD-093 (P < 0.01; Fig. 3C ). Therefore, it seems that ThRII R537P -mutant cells have acquired novel properties, including constitutive EMT and high rates of migration and invasion that may contribute to the tumorigenicity of A253 in vivo. This phenotype is clearly distinct from that of the SqCC/Y1 TGFBR2 E526Q -mutant cells, which seem to have lost all responses to TGFh. Moreover, the unique in vitro properties of A253 cells were also retained in vivo. As shown in Fig. 3D , A253 cells gave rise to poorly differentiated invasive squamous cell carcinomas in vivo. Consistent with the in vitro studies, the levels of pSmad2 expressed by the tumor cells were almost undetectable. On the other hand, the same tumor cells showed strong nuclear staining for pSmad1 and/or pSmad5, on a par with that seen in endothelial cells of the tumor-associated capillaries as well as basal and suprabasal keratinocytes in the epidermis. Interestingly, basal and suprabasal keratinocytes in the epidermis displayed the strongest pSmad1 and/or pSmad5 immunostaining, whereas cells in the stratum granulare and stratum corneum expressed pSmad2, suggesting that the two arms of TGFh signaling might be activated at different stages of keratinocyte differentiation in vivo.
Our results suggest that TGFh-induced BMP-Smad activation in keratinocytes involves partnering of the ThRII receptor with and activation of one of the BMP pathway type I receptors. As shown in Fig. 4 , none of the keratinocyte cell lines (HaCaT, A253, and SqCC/ Y1) expressed Alk-1 mRNA, whereas Alk-2, Alk-3, Alk-5, and Alk-6 mRNAs were all expressed in each of the three cell lines (Fig. 4) . Although Alk-3 and Alk-6 receptors can activate BMP-Smads, they have not been tied to TGFh signaling. On the other hand, as Alk-2 has been previously shown to act as a receptor for TGFh, it is the leading candidate type I receptor to mediate the activation of BMP-Smads in HaCaT and A253 cells.
Finally, we examined the effects of TGFBR2 R537P on coexpressed wild-type ThRII signaling. First, we compared the phenotype of FaDu Â A253 somatic cell hybrid cells derived from the esophageal carcinoma line FaDu and A253 (15) with that of the two parental cell lines. FaDu cells are null for the MADH4 gene but express wild-type TGFBR2 (5, 7), whereas A253 is homozygous for the TGFBR2 R537P mutation. As shown in Fig. 5A , treatment of FaDu cells with TGFh resulted in activation of Smad2 and Smad3, which was inhibitable by SD-093, whereas A253 cells constitutively expressed pSmad1 and pSmad5 but failed to activate Smad2 or Smad3 in response to TGFh. In contrast, treatment of FaDu Â A253 hybrid cells with TGFh resulted in activation of both Smad2 and Smad3 (Fig. 5A ). Most importantly, SD-093 treatment inhibited this induction, suggesting that the presence of wild-type ThRII restored TGFh-mediated R-Smad phosphorylation in a ThRI (Alk-5)-dependent mechanism. Moreover, the levels of pSmad1 and pSmad5 seemed to be somewhat lower in FaDu Â A253 than in parental A253 cells (Fig. 5A) . As shown previously, the high levels of activated pSmad1 and pSmad5 in A253 cells were not affected by SD-093 treatment (Fig. 5B) . In contrast, in the FaDu Â A253 hybrid cells, TGFh-activated Smad2 and Smad3 underwent rapid dephosphorylation on SD-093 treatment, with kinetics similar to those observed in HaCaT (Fig. 5B) . In aggregate, these results indicate that the TGFBR2 R537P mutant is recessive over the wild-type receptor and that the associated activated cell phenotype only becomes manifest in cells that are either Figure 3 . Effects of ThR-kinase inhibitors on cellular responses. A, treatment of HaCaT cells with TGFh (100 pmol/L) for 72 h induced EMT associated with subcellular redistribution of F-actin from a submembranous location to incorporation into stress fibers ( ). TGF treatment also resulted in redistribution of E-cadherin from a membranous to cytoplasmic and cytoplasmic and perinuclear localization ( ). TGFh-induced actin reorganization as well as E-cadherin redistribution were inhibited by SD-093 (1 Amol/L) or LY2109761 (2 Amol/L) pretreatment. Moreover, drug treatments alone seemed to induce a stronger peripheral F-actin and predominantly membrane-associated E-cadherin staining pattern compared with vehicle-treated (DMSO) control cells. SqCC/Y1 cells showed membrane-associated F-actin and E-cadherin staining. These cells had a strongly epithelial morphology, which was unaffected by treatment with either TGFh or any of the ThR inhibitors. In contrast, A253 cells displayed diffuse cytoplasmic F-actin staining, whereas E-cadherin was predominantly perinuclear. These cells therefore seemed to be in a state of EMT, which was unaffected by either TGFh or SD-093 treatment. However, treatment with LY2109761 resulted in redistribution of F-actin to the cell periphery and of E-cadherin to the membrane and restoration of an epithelioid morphology. B, in vitro migration assays were performed as described in Materials and Methods. In HaCaT cells, treatment with TGFh (100 pmol/L) for 24 h induced a 10-fold increase in the rate of cell migration. This increase was completely inhibited by pretreating cells with either SD-093 (1 Amol/L) or LY2109761 (2 Amol/L). SqCC/Y1 cells had a very low basal rate of cell migration, which was unaffected by TGFh or with either of the inhibitors (SD-093 or LY2109761). In contrast, A253 cells migrated at a rate almost 20 times higher than that of HaCaT cells. Cell migration was not affected by either TGFh or SD-093 treatment. In contrast, treatment with LY2109761 reduced migration by f50% independently of the presence of exogenous TGFh (P < 0.01, Student's t test). C, vehicle control; T, TGFh; SD, SD-093; LY, LY2109761. C, in vitro invasion assays were performed as described in Materials and Methods. A253 cells were constitutively highly invasive. Neither treatment with TGFh (100 pmol/L) nor treatment with SD-093 (1 Amol/L) had any effect on A253 invasiveness. However, LY2109761 (1 Amol/L) inhibited invasion by f50% independently of the presence of TGFh (P < 0.01, Student's t test). This effect of LY2109761 was not due to growth arrest or cell death due to drug toxicity because treatment with this agent did not affect total A253 cell numbers (data not shown). D, 10 6 A253 cells were injected s.c. into 8-to 9-wk-old athymic nude mice and allowed to give rise to palpable tumors. Sections from formaldehyde-fixed, paraffin-embedded, A253-derived tumors were stained by H&E as well as for pSmad2 and pSmad1/5. Magnification, Â200. A253 cells gave rise to poorly differentiated invasive squamous cell carcinomas. pSmad2 expressed by the tumor cells was almost undetectable and certainly significantly lower than the amounts expressed by normal cells as illustrated by differentiated keratinocytes in the overlying epidermis. On the other hand, the same tumor cells showed strong nuclear staining for pSmad1 and/or pSmad5, similar to that seen in endothelial cells of the tumor-associated capillaries. Interestingly, basal and suprabasal keratinocytes in the epidermis displayed the strongest pSmad1 and/or pSmad5 immunostaining, whereas pSmad2 was predominantly expressed in the stratum granulare and stratum corneum, suggesting the possibility that the two arms of TGFh signaling are activated at different stages of keratinocyte differentiation in vivo.
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To further characterize the function of the TGFBR2 mutants in the context of wild-type receptor expression, wild-type and mutant ThRII were coexpressed in the TGFBR2-null mammary cancer line T47D (10) . Cotransfection of wild-type TGFBR2 and TGFBR2
E526Q
induced 3TP-lux reporter activity in direct proportion to the amount of wild-type TGFBR2 cDNA (Fig. 5C, top left) . Thus, the TGFBR2 E526Q mutant confers a null phenotype and has no dominant-negative properties. Similarly, expression of the TGFBR2 R537P mutant by itself failed to induce 3TP-lux reporter activity. However, in the presence of both wild-type and TGFBR2
R537P
-mutant receptor, the net reporter gene activity was approximately equal to that obtained with 100% wild-type receptor. Moreover, treatment with either of the two inhibitors, SD-093 or LY2109761, resulted in inhibiting 3TP-lux activity (data not shown). Essentially similar results were obtained with the SBE4-luc reporter gene construct (Fig. 5C, top right) . On the other hand, when we used the Col7A1-luc reporter, the combination of wild-type and TGFBR2
mutant receptor seemed to have an intermediate activity, suggesting that the mutant was not contributing to Col7A1-luc induction (Fig. 5C, bottom left) . When we examined the effects of the two TGFBR2 mutants on the TGFh-repressed Del-5-myc-luc reporter gene construct, coexpression of wild-type ThRII and either of the two mutants resulted in a dose-dependent decrease in Del-5-myc-luc activity, which was proportional to the amount of wildtype receptor transfected (Fig. 5C, bottom right) . However, in the sole presence of the TGFBR2 R537P mutant, the level of Del-5-mycluc activity seemed to be somewhat higher than in the presence of the inactive TGFBR2 E526Q mutant, suggesting that the TGFBR2 R537P mutant has modest dominant-negative activity in this case. Total levels of ThRII receptor expression were similar across all conditions (Fig. 5D ). In aggregate, these results indicate that the ThRII E526Q mutant is a true loss-of-function mutant that has no dominant-negative effect on coexpressed wild-type receptor. The ThRII R537P mutant is equally incapable of activating classic TGFh target genes when it is the sole receptor gene expressed (as is the case in A253 cells). On the other hand, in the presence of wild-type receptor, the ThRII R537P mutant seems to have retained its capability to activate some target genes (3TP-lux and SBE4-luc), whereas it is inactive with respect to Col7A1-luc and modestly dominant negative with regard to Del-5-myc-luc. These results suggests that, in cells that are homozygous for this mutant, the classic TGFh-regulated gene expression program is eliminated, whereas in the heterozygous situation the TGFh-regulated gene expression program is likely to be qualitatively altered, giving rise to complex changes in the cellular phenotype.
Discussion
Our first important finding is that, besides the canonical TGFhSmads Smad2 and Smad3, TGFh also activates the BMP-Smads Smad1 and Smad5 in HaCaT human keratinocytes (Fig. 6 ). This ability of TGFh to cross-activate BMP-Smads has also been observed in several other cell types, including human endothelial cells (16) , rat intestinal epithelial cells (17) , mouse mammary epithelial cells (18) , and human mammary carcinoma cells (19) . As in endothelial cells, TGFh-induced BMP-Smad activation seems to be dependent on Alk-5 kinase activity, as it was inhibitable by several different Alk-5 chemical inhibitors. Although these inhibitors also target the activin receptors Alk-4 and Alk-7, the fact that activin A was not able to activate BMP-Smads practically excludes the involvement of Alk-4 or Alk-7 in BMP-Smad activation. In endothelial cells, ThRII mediates TGFh-dependent Smad2 and Smad3 activation by partnering with Alk-5 (ThRI) and Smad1 and Smad5 activation by partnering with Alk-1 (20) . This is clearly not the case in HaCaT, as these cells do not express Alk-1 mRNA (Fig. 4) . Based on their ability to mediate BMP-Smad activation and mRNA expression in keratinocytes, other candidates include Alk-2, Alk-3, and Alk-6. Originally identified as a type I receptor partner for ThRII, Alk-2 (initially named Tsk7L; ref. 21 ) usually functions as a BMP type I receptor (22) . However, Alk-1 and Alk-2 are most similar among the type I receptors. Moreover, Alk-2 is able to weakly bind TGFh when overexpressed in COS cells, as long as the ThRII receptor is coexpressed, a characteristic of ThRI (21, 23, 24) . Although Alk-2 is able to complex with ThRII independently of TGFh, this requires the kinase activity of ThRII (25) . Moreover, TGFh is able to activate BMP-Smads through Alk-2 in other types of untransformed epithelial cells (16) (17) (18) . Thus, Alk-2 is the most likely candidate to partner with ThRII and activate Smad1/5 in keratinocytes. Studies to confirm this hypothesis are in progress.
The ability of the ThRII receptor to signal through two distinct type I receptors may be explained by several possible models: ThRII may form heterodimeric complexes with either Alk-5 or Alk-x, with the two types of complexes being in some sort of equilibrium. Alternatively, the three proteins may form heteromeric complexes that include both Alk-5 and Alk-x. In endothelial cells, Goumans et al. (20) reported that Alk-1 and Alk-5 form heteromeric complexes, most strongly in the presence of TGFh. In addition, efficient heteromeric complex formation between Alk-1 and Alk-5 required the presence of ThRII within the complexes. In endothelial cells, active Alk-5 is required to be present within heteromeric complexes for Alk-1 activation to take place. This is consistent with our finding in HaCaT cells that BMP-Smad activation is dependent on ThRI (Alk-5) kinase activity. In the case of endothelial cells, Goumans et al. (20) found no evidence for direct phosphorylation of Alk-1 by the Alk-5 kinase, but this remains to be shown in HaCaT cells. Besides Alk-5, ThRII is also required for BMP-Smad activation by Alk-1 in endothelial cells, as this response to TGFh is lost in ThRII-null cells. This is also consistent with our finding that treatment with the dual ThRII/Alk-5 inhibitor LY2109761 abrogated BMP-Smad activation not only in HaCaT cells but also in A253 cells, in which this activation is no longer dependent on Alk-5.
In vitro, TGFh seems to be able to simultaneously induce pSmad2/3 and pSmad1/5 in keratinocytes (Fig. 1A) . Of note, immunostaining of normal epidermis (Fig. 3D) revealed that pSmad1/5 is predominantly expressed in basal and suprabasal keratinocytes, whereas pSmad2 is expressed in more differentiated cell layers, suggesting the possibility that each of the two TGFh signaling arms may be activated at different stages of keratinocyte differentiation in vivo. In contrast, in the A253 TGFBR2 R537P -mutant cells, TGFh no longer induces phosphorylation of Smad2 or Smad3, whereas Smad1 and Smad5 seem to be constitutively activated. These cells are refractory to TGFh-induced growth arrest, although they seem to be in a permanent EMT-like state, highly motile, and invasive and to express high levels of the TGFh target proteins, plasminogen activator inhibitor-1 (PAI-1) and fibronectin, independently of treatment with TGFh (26, 27) . Moreover, treatment of A253 cells with the dual ThR kinase inhibitor LY2109761 resulted in dephosphorylation of pSmad1/5, induction of an epithelioid phenotype, and inhibition of cell migration. In aggregate, these findings strongly suggest that, in Figure 5 . Effects of coexpression of wild-type and mutant ThRII gene. A, activation and dephosphorylation of Smads in FaDu Â A253 somatic hybrid cells. Treatment of FaDu Â A253 with TGFh (100 pmol/L) for 1 h induced phosphorylation of Smad2 and pSmad3 but not of Smad1 and Smad5. This phenotype was similar to that of parental FaDu cells that express wild-type ThRII. In both cell lines, TGFh-induced Smad2 and Smad3 phosphorylation was inhibitable by the ThRI kinase inhibitor SD-093. In contrast, TGFh failed to induce phosphorylation of Smad2 and Smad3 in parental A253 cells that express the TGFBR2 R537P mutant. B, SD-093 dephosphorylation assays were performed as described in Materials and Methods. In FaDu Â A253 cells, TGFh-activated pSmad2 and pSmad3 underwent rapid dephosphorylation in response to SD-093 treatment with a t 1/2 of 45 min. In contrast, parental A253 cells expressed high levels of pSmad1 and pSmad5, which were unaffected by SD-093. Top right, FaDu Â A253 cells expressed much lower reduced levels of pSmad1 and pSmad5 than A253 cells. C, wild-type and mutant ThRII cDNAs were coexpressed in ThRII-null T47D cells. Top left, transfection of E526Q (.) or R537P (n) alone had no effect on 3TP-lux reporter gene activity. When wild-type ThRII was coexpressed with the E526Q mutant, the level of 3TP-lux activity increased in linear proportion with the amount of wild-type ThRII. Thus, the E526Q has no intrinsic activity nor does it act in a dominant-negative fashion on wild-type receptor. In contrast, when wild-type ThRII was coexpressed with the R537P mutant, 3TP-lux activity was similar to that induced by wild-type receptor alone. Thus, although the R537P mutant has no ability to induce 3TP-lux activity on its own, it seems to complement the ability of wild-type receptor to activate this target gene. 3TP-lux activation was inhibited in the presence of either SD-093 or LY2109761. Transfection of E526Q or R537P alone had no effect on SBE4-luc (top right ) or Col7A1-luc (bottom left ) activity. When wild-type ThRII was coexpressed with the E526Q mutant, the levels of SBE4-luc (and Col7A1-luc) activity increased in linear proportion with the amount of wild-type ThRII. Thus, the E526Q mutant has no intrinsic activity nor does it act in a dominant-negative fashion on wild-type receptor. In contrast, when wild-type ThRII was coexpressed with the R537P mutant, SBE4-luc (and Col7A1-luc) activity was close to that expected from wild-type receptor alone. Thus, although the R537P mutant has no apparent ability to induce SBE4-luc (and Col7A1-luc) activity by itself, it complements the ability of wild-type receptor to activate this target gene. Bottom right, expression of either E526Q or R537P was associated with higher Del-5-myc -luc activity than wild-type ThRII. When wild-type ThRII was coexpressed with the E526Q or R537P mutant, the level of Del-5-myc -luc activity decreased in linear proportion with the amount of wild-type ThRII. Thus, E526Q and R537P mutants seemed to have lost the ability to induce repression of c-myc , which is reversed with the wild-type receptor. D, T47D cells cotransfected with wild-type and mutant ThRII cDNAs were subjected to Western blot analysis using antibody specific to ThRII protein. Total ThRII protein was expressed in equivalent amounts in all transfection conditions. Mock-transfected ThRII-null T47D cells were included as negative controls.
keratinocytes, TGFh/Alk-5-dependent activation of Smad2 and Smad3 results in growth arrest, whereas the TGFh-induced response to tissue injury, including EMT and cell migration, is mediated by activation of pSmad1 and pSmad5. If this hypothesis is correct, one might speculate that the uncoupling of these two responses commonly seen in epithelial carcinomas might result from inactivation of the Smad2/3 pathway on the one hand with concurrent activation of the Smad1/5 pathway on the other.
Our second major finding is that cancer-associated mutations of the ThRII gene can be associated with at least two distinct phenotypes (Fig. 6) . The first is represented by the TGFBR2 E526Q mutant found in SqCC/Y1 cells. We had previously shown that this mutation abrogates ThRII kinase activity (5, 27) . In this case, all downstream responses to TGFh are eliminated, including phosphorylation of Smads, target gene regulation, fibronectin and PAI-1 production, growth arrest, EMT, and cell migration (26, 27) . This phenotype is displayed by SqCC/Y1 cells, which are homozygous for the TGFBR2 E526Q mutation, as well as by TGFBR2-null cells in which the mutant receptor is expressed by itself (5, 26, 27) . On the other hand, in cells in which the TGFBR2 E526Q mutant is coexpressed with wild-type TGFBR2, the cellular response to TGFh seems to be dictated by the wild-type receptor. Thus, transient cotransfection experiments using ThRII-null recipient cells showed that TGFh target reporter gene activation was proportional to the amount of wild-type receptor expressed (Fig. 5) . Thus, the
TGFBR2
E526Q mutant has a true loss-of-function phenotype that does not affect the function of coexpressed wild-type receptor in a dominant-negative manner. As cells that are heterozygous for mutants of this type display attenuated TGFh signaling, germ-line mutations of this type may be associated with increased cancer susceptibility, similarly to TGFh1 heterozygous mice (28, 29) and dominant-negative ThRII transgenic mice (30) .
The second type of ThRII mutant is exemplified by the TGFBR2 R537P mutation found in A253 cells (Fig. 6) . We had previously shown that this mutation is associated with a constitutively high intrinsic ThRII kinase activity and production of PAI-1 and fibronectin (5, 26, 27) . In cells in which this mutant receptor is expressed by itself, TGFh target gene regulation is largely eliminated (see Fig. 5 and refs. 26, 27) . Consistent with these findings, A253 cells that are homozygous for the TGFBR2 R537P mutation have lost TGFh-dependent Smad2/3 activation. However, in contrast to TGFBR2 E526Q -mutant cells, A253 cells display constitutive activation of the BMP-Smad1/5 pathway, which is independent not only of exogenous TGFh but also of ThRI (Alk-5) kinase activity, as the Alk-5 kinase inhibitor SD-093 failed to induce dephosphorylation of these Smads. On the other hand, BMP-Smad activation was clearly dependent on ThRII receptor kinase activity, as it could be abrogated using the dual ThR kinase inhibitor LY2109761. It is theoretically possible that TGFh-independent BMP-Smad activation in A253 cells is induced by BMP. However, the fact that Figure 6 . Proposed model of ThR signaling pathway in normal human keratinocytes and squamous carcinoma cells. In normal human keratinocytes (exemplified by HaCaT cells), TGFh binds to the ThRII and activates the classic Smad2/3 pathway via ThRI (Alk-5). In addition, our studies indicate that TGFh can activate BMP-Smads (Smad1 and Smad5) in a ThRI (Alk-5)-dependent manner. In analogy with endothelial cells, we assume that one of the BMP type I receptors is involved in this process (Alk-x), with Alk-2 being the leading candidate. Moreover, one might speculate that the Smad2/3 arm of the signaling pathway mediates the homeostatic function of TGFh, whereas the Smad1/5 arm is involved in the tissue injury response. In the case of some cancer-associated ThRII mutants (exemplified by ThRII E526Q in SqCC/Y1 cells), both arms of the TGFh/Smad pathway are abrogated. In contrast, in the case of ThRII
R537P
-mutant A253 cells, the ThRII/Alk-5/Smad2/3 pathway is also abrogated, resulting in loss of TGFh-mediated growth control. However, the Smad1/5 pathway is constitutively activated in an Alk-5-independent manner, apparently resulting in increased EMT, cell migration, and invasion. Thus, this type of mutant has a dual-function phenotype, associated with loss of one arm of the TGFh/Smad pathway and activation of the second arm. Moreover, our studies indicate that this gain of function is inhibitable by the dual-receptor kinase inhibitor LY2109761, while it is resistant to selective ThRI kinase inhibitors.
LY2109761 is capable of abrogating the BMP-Smad activation essentially rules this out, as this compound belongs to the series of pyrazole Alk-4, Alk-5, and Alk-7 inhibitors described by Peng et al. (13) . These compounds are incapable of inhibiting BMP4-induced xVent2-luciferase activity or reversing BMP4-mediated growth inhibition at concentrations up to 20 Amol/L (13). In fact, these compounds even potentiate the xVent2-lux BMP4 response in mammary epithelial cells at concentrations as low as 0.25 Amol/L.
Although we have not yet elucidated the biochemical mechanisms underlying the TGFBR2
-mutant cell phenotype, lessons learned from other TGFBR2 mutants suggest several reasonable possibilities. For example, Chen et al. (31) reported that, in cells overexpressing kinase-inactive truncated ThRII receptors, TGFhmediated induction of growth inhibition was abrogated, whereas the induction of fibronectin, PAI-1, and JunB was retained. Recently, Goumans et al. (20) showed that a COOH-terminally truncated ThRII construct dominant negatively inhibited constitutively active Alk-5-dependent activation of the Alk-1/Smad1/5 pathway in primary endothelial cells. In addition, expressing a COOH-terminally truncated ThRII mutant in Alk-5-null cells resulted in TGFh binding to Alk-1 even in the absence of Alk-5. This shows that a structural mutation of ThRII can dramatically alter its affinity for Alk partners. Thus, perhaps the most likely model is that disease-associated mutations in either the TGFBR1 or TGFBR2 receptor genes can affect protein-protein interactions and, specifically, obviate the requirement for Alk-5 in the formation of ThRII/Alk-x complexes and Alk-x activation. Alternatively, mutations might disrupt the interaction of ThRII with Alk-5 while favoring its interaction with alternative Alk-x, somehow resulting in the preferential activation of the Alk-x/Smad1-Smad5 pathway. Whichever mechanism is responsible for the Alk-5-independent and ligand-independent activation of Smad1 and Smad5 in A253 cells is likely to also account for the inability of TGFh to activate Smad2 and Smad3 in these cells. The fact that activin treatment of A253 cells resulted in the expected phosphorylation of Smad2 and Smad3 shows that both Smads are expressed and able to be appropriately phosphorylated by receptor kinases. Thus, the fact that Smad2 and Smad3 are no longer activated suggests that Alk-5 no longer participates in the TGFh/ThRII/Alk-5 receptor complex or is no longer activated by the ThRII R537P mutant. We are currently investigating this possibility. Moreover, in endothelial cells, Alk-1 not only induces cellular responses opposite to those of Alk-5 but also directly antagonizes Alk-5-induced transcriptional responses (20, 32) . These findings suggest that, in a situation in which the Alk-x/Smad1/5 pathway is selectively hyperactivated (as is the case in A253 cells), this negative cross-talk could further contribute to shutting down signaling through the Alk-5/Smad2/3 pathway.
In contrast to cells that are homozygous for the TGFBR2 R537P mutation (as is the case in A253), in cells in which the R537P mutant is coexpressed in conjunction with wild-type ThRII, responses to TGFh seem to be dictated by the wild-type receptor. Thus, in FaDu Â A253 hybrid cells (15) , the TGFh-mediated activation of Alk-5/Smad2/3 and dephosphorylation in response to SD-093 seem to have been restored, and the cells no longer express constitutively high levels of pSmad1 and pSmad5. In addition, the cellular responses of FaDu Â A253 cells to TGFh were similar to those of HaCaT keratinocytes (15) . Similarly, transient cotransfection experiments of TGFBR2 R537P mutant and wild-type TGFBR2 into TGFBR2-null recipient cells showed that TGFh-specific target reporter gene activation was similar to that seen with wild-type receptor alone (Fig. 5) . Thus, the TGFBR2 R537P mutant does not seem to affect the function of coexpressed wild-type receptor in a dominant-negative or dominant-active manner. However, the question whether pSmad1/5-dependent transcripts are upregulated under these conditions is still under investigation.
In cancer, mutations of the TGFBR2 gene seem to be homozygous; that is, the cancers have undergone loss of the wild-type allele or both TGFBR2 alleles have undergone missense mutations (3, 33) . For the TGFBR2 E526Q type of mutation, the predominant selective advantage would be loss of TGFh-mediated growth arrest. Even the putative intermediate heterozygous state would likely be associated with an overall attenuation of TGFh signal and thus confer a growth advantage. In the homozygous state, the TGFBR2 R537P type of mutant provides two selective advantages: loss of homeostatic growth control coupled with constitutive EMT, high motility, and high invasion. In this case, our transfection assays suggest that the heterozygous state may not be associated with an altered phenotype. On the other hand, Lu et al. (34, 35) have described a germ-line mutation of the TGFBR2 gene (T315M) in a family with hereditary nonpolyposis colorectal cancer that is incapable of mediating growth inhibition by TGFh but has retained the ability to induce PAI-1 in response to TGFh treatment. Thus, this mutant seems to have a dual phenotype similar to that of the R537P mutant, indicating that heterozygous carriers of this type of mutant may also have increased cancer susceptibility. These studies illustrate that further characterization of individual mutants, in terms of their profiles of Smad activation and a search for alternative signaling pathways, will be key in devising targeted therapeutic strategies for cancer and other diseases that are driven by mutations in ThR genes.
